CY1124972T1 - Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης - Google Patents
Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινηςInfo
- Publication number
- CY1124972T1 CY1124972T1 CY20221100102T CY221100102T CY1124972T1 CY 1124972 T1 CY1124972 T1 CY 1124972T1 CY 20221100102 T CY20221100102 T CY 20221100102T CY 221100102 T CY221100102 T CY 221100102T CY 1124972 T1 CY1124972 T1 CY 1124972T1
- Authority
- CY
- Cyprus
- Prior art keywords
- heavy chain
- human
- immunospherin
- gene segments
- antigen
- Prior art date
Links
- 241000699670 Mus sp. Species 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 6
- 239000000427 antigen Substances 0.000 abstract 3
- 108091007433 antigens Proteins 0.000 abstract 3
- 102000036639 antigens Human genes 0.000 abstract 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 2
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 2
- 241000699666 Mus <mouse, genus> Species 0.000 abstract 2
- 230000003053 immunization Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Environmental Sciences (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Παρέχονται ποντικοί, διαθέτοντες έναν περιορισμένο τόπο βαριάς αλυσίδας ανοσοσφαιρίνης, ο οποίος τόπος χαρακτηρίζεται από ένα μόνον, πολυμορφικό, ανθρώπινο VH γονιδιακό τμήμα, μια πληθώρα ανθρώπινων DH γονιδιακών τμημάτων και μια πληθώρα JH γονιδιακών τμημάτων. Παρέχονται μέθοδοι δημιουργίας αλληλουχιών αντισωμάτων, που προσδένουν ένα αντιγόνο (π.χ., ένα ιικό αντιγόνο), που περιλαμβάνουν ανοσοποίηση ενός ποντικού με ένα αντιγόνο ενδιαφέροντος, ο οποίος ποντικός διαθέτει ένα μόνον, ανθρώπινο VH γονιδιακό τμήμα, μια πληθώρα ανθρώπινων DH γονιδιακών τμημάτων και μια πληθώρα JH γονιδιακών τμημάτων, στον ενδογενή τόπο βαριάς αλυσίδας ανοσοσφαιρίνης.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161547974P | 2011-10-17 | 2011-10-17 | |
US201261597969P | 2012-02-13 | 2012-02-13 | |
US201261658459P | 2012-06-12 | 2012-06-12 | |
PCT/US2012/060487 WO2013059230A1 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
EP12783456.2A EP2627773B1 (en) | 2011-10-17 | 2012-10-17 | Restricted immunoglobulin heavy chain mice |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1124972T1 true CY1124972T1 (el) | 2023-01-05 |
Family
ID=47144131
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100960T CY1119335T1 (el) | 2011-10-17 | 2017-09-12 | Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης |
CY20221100102T CY1124972T1 (el) | 2011-10-17 | 2022-02-07 | Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20171100960T CY1119335T1 (el) | 2011-10-17 | 2017-09-12 | Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης |
Country Status (26)
Country | Link |
---|---|
US (5) | US10246509B2 (el) |
EP (3) | EP4074833A1 (el) |
JP (6) | JP6271435B2 (el) |
KR (6) | KR20160098514A (el) |
CN (3) | CN104024418B (el) |
AU (4) | AU2012326283C1 (el) |
BR (1) | BR112014008775A8 (el) |
CA (1) | CA2850534A1 (el) |
CY (2) | CY1119335T1 (el) |
DK (2) | DK3216871T3 (el) |
ES (2) | ES2640139T3 (el) |
HR (2) | HRP20220253T1 (el) |
HU (2) | HUE057680T2 (el) |
IL (5) | IL292030B2 (el) |
IN (1) | IN2014CN03572A (el) |
LT (2) | LT3216871T (el) |
MX (1) | MX355062B (el) |
MY (1) | MY172946A (el) |
PL (2) | PL3216871T3 (el) |
PT (2) | PT3216871T (el) |
RS (2) | RS56458B1 (el) |
RU (2) | RU2743589C2 (el) |
SG (3) | SG11201401181YA (el) |
SI (2) | SI3216871T1 (el) |
WO (1) | WO2013059230A1 (el) |
ZA (1) | ZA201402455B (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
HUE045591T2 (hu) | 2010-02-08 | 2019-12-30 | Regeneron Pharma | Közönséges könnyûláncú egér |
US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
RU2750219C2 (ru) | 2010-08-02 | 2021-06-24 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
RS59661B2 (sr) | 2011-02-25 | 2023-06-30 | Regeneron Pharma | Adam6 miševi |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
AU2012311288B2 (en) | 2011-09-19 | 2017-08-17 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
CA2859408C (en) | 2011-12-20 | 2020-06-16 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PL3597037T3 (pl) * | 2012-06-12 | 2021-10-25 | Regeneron Pharmaceuticals, Inc. | Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny |
MY178882A (en) * | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
WO2015112790A2 (en) * | 2014-01-24 | 2015-07-30 | Children's Medical Center Corporation | High-throughput mouse model for optimizing antibody affinities |
ES2762640T3 (es) | 2014-03-21 | 2020-05-25 | Regeneron Pharma | Proteínas VL de unión a antígeno que exhiben diferentes características de unión |
WO2015143414A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
US20170121399A1 (en) | 2014-05-16 | 2017-05-04 | Ablynx N.V. | Improved immunoglobulin variable domains |
CN107438622A (zh) | 2015-03-19 | 2017-12-05 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
CN108777951B (zh) | 2016-01-13 | 2021-11-05 | 瑞泽恩制药公司 | 具有包括改造的多样性簇的免疫球蛋白重链可变区的非人动物及其用途 |
RU2018130010A (ru) | 2016-02-16 | 2020-03-17 | Регенерон Фармасьютикалз, Инк. | Животные, отличные от человека, имеющие мутантный ген кинурениназы |
KR102628909B1 (ko) | 2016-05-20 | 2024-01-25 | 리제너론 파마슈티칼스 인코포레이티드 | 다중 가이드 RNAs를 이용한 면역학적 내성 파괴 방법 |
PT3462853T (pt) | 2016-06-03 | 2023-04-21 | Regeneron Pharma | Animais não humanos que expressam desoxinucleotidiltransferase terminal exógena |
AU2017391167B2 (en) | 2016-11-04 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
CN108265035A (zh) * | 2016-12-30 | 2018-07-10 | 深圳先进技术研究院 | 一种进化噬菌体宿主特异性的方法 |
US20210345591A1 (en) | 2017-12-05 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
CN112040769B (zh) | 2018-03-24 | 2023-05-16 | 瑞泽恩制药公司 | 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途 |
SG11202008620VA (en) | 2018-03-26 | 2020-10-29 | Regeneron Pharma | Humanized rodents for testing therapeutic agents |
CN112312766A (zh) | 2018-06-14 | 2021-02-02 | 瑞泽恩制药公司 | 在免疫球蛋白重链编码序列中具有dh-dh重排能力的非人动物 |
US20220330532A1 (en) | 2019-06-05 | 2022-10-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
CN114901678A (zh) | 2019-12-02 | 2022-08-12 | 瑞泽恩制药公司 | 肽-mhc ii蛋白构建体及其用途 |
JP2023540808A (ja) | 2020-09-11 | 2023-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗原特異的抗体の同定及び産生 |
JP2024500399A (ja) | 2020-12-16 | 2024-01-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化Fcアルファ受容体を発現するマウス |
TW202241934A (zh) * | 2020-12-23 | 2022-11-01 | 美商再生元醫藥公司 | 編碼錨定修飾抗體之核酸及其用途 |
WO2023179620A1 (en) * | 2022-03-21 | 2023-09-28 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin and mhc loci |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6255458B1 (en) * | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
EP1978033A3 (en) * | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
EP1500329B1 (en) | 1996-12-03 | 2012-03-21 | Amgen Fremont Inc. | Human antibodies that specifically bind human TNF alpha |
CN1203922A (zh) | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
FI105105B (fi) * | 1998-02-27 | 2000-06-15 | Finnish Immunotechnology Ltd O | Itsereplikoiva DNA-vektori immunisoimiseksi HIV:ta vastaan |
AU5043200A (en) | 1999-05-27 | 2000-12-18 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
CN101498731A (zh) * | 2000-05-18 | 2009-08-05 | 日本烟草产业株式会社 | 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途 |
US20020028488A1 (en) * | 2000-06-19 | 2002-03-07 | Sujay Singh | Transgenic avian species for making human and chimeric antibodies |
US7129084B2 (en) | 2000-08-03 | 2006-10-31 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
TWI255272B (en) | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
JP4115281B2 (ja) | 2001-05-11 | 2008-07-09 | キリンファーマ株式会社 | ヒト抗体λ軽鎖遺伝子を含むヒト人工染色体、および子孫伝達可能な該ヒト人工染色体を含む非ヒト動物 |
US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
ATE514717T1 (de) | 2002-07-18 | 2011-07-15 | Merus B V | Rekombinante produktion von antikörpermischungen |
GB0228210D0 (en) | 2002-12-03 | 2003-01-08 | Babraham Inst | Single chain antibodies |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
WO2004106375A1 (en) | 2003-05-30 | 2004-12-09 | Merus Biopharmaceuticals B.V. I.O. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
AU2004257292A1 (en) | 2003-07-15 | 2005-01-27 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
US20050153392A1 (en) | 2003-08-11 | 2005-07-14 | Roland Buelow | Transgenesis with humanized immunoglobulin loci |
EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
RU2251699C1 (ru) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
WO2005038001A2 (en) | 2003-10-14 | 2005-04-28 | Therapeutic Human Polyclonals, Inc. | Improved transgenesis by sperm-mediated gene transfer |
CN101076542A (zh) * | 2004-09-13 | 2007-11-21 | 伊沃詹尼克斯有限公司 | 特异性针对肝细胞癌和其他癌的抗体及其用途 |
EP1874817A2 (en) | 2005-04-29 | 2008-01-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
BRPI0706750A2 (pt) | 2006-01-25 | 2011-04-05 | Univ Erasmus Medical Ct | geração de anticorpos de cadeia pesada em animais transgênicos |
JP5514539B2 (ja) | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
LT2602323T (lt) | 2007-06-01 | 2018-04-10 | Open Monoclonal Technology, Inc. | Kompozicijos ir būdai endogeninių imunoglobulinų genams slopinti ir transgeniniams žmogaus idiotipo antikūnams gaminti |
WO2009013620A2 (en) | 2007-06-11 | 2009-01-29 | Erasmus University Medical Center Rotterdam | Homologous recombination |
WO2009097006A2 (en) * | 2007-08-10 | 2009-08-06 | Medarex, Inc. | Hco32 and hco27 and related examples |
WO2009042589A1 (en) * | 2007-09-24 | 2009-04-02 | Vanderbilt University | Monoclonal antibodies to respiratory syncytial virus and uses thereof |
KR20100103810A (ko) | 2007-12-10 | 2010-09-28 | 알리바 바이오파마수티컬스, 아이엔씨. | 동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법 |
ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
EP2271758B1 (en) | 2008-04-14 | 2018-09-12 | Innovative Targeting Solutions Inc. | Sequence diversity generation in immunoglobulins |
CN102099378B (zh) * | 2008-05-16 | 2016-01-20 | 埃博灵克斯股份有限公司 | 针对CXCR4和其他GPCRs的氨基酸序列以及包含所述氨基酸序列的多肽 |
US20110123527A1 (en) | 2008-05-23 | 2011-05-26 | Hiroaki Shizuya | Method of generating single vl domain antibodies in transgenic animals |
WO2010039900A2 (en) | 2008-09-30 | 2010-04-08 | Aliva Biopharmaceuticals, Inc. | Non-human mammals for the production of chimeric antibodies |
ES2613730T3 (es) | 2008-12-18 | 2017-05-25 | Erasmus University Medical Center Rotterdam | Animales transgénicos no humanos que expresan anticuerpos humanizados y su uso |
GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
KR20120027055A (ko) * | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
SG181477A1 (en) | 2009-12-10 | 2012-07-30 | Regeneron Pharma | Mice that make heavy chain antibodies |
US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
HUE045591T2 (hu) | 2010-02-08 | 2019-12-30 | Regeneron Pharma | Közönséges könnyûláncú egér |
US20130185821A1 (en) | 2010-02-08 | 2013-07-18 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
NZ605966A (en) | 2010-06-17 | 2015-04-24 | Kymab Ltd | Animal models and therapeutic molecules |
RU2750219C2 (ru) | 2010-08-02 | 2021-06-24 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
EP2638155A1 (en) | 2010-11-08 | 2013-09-18 | Kymab Limited | Cells & vertebrates for enhanced somatic hypermutation and class switch recombination |
RS59661B2 (sr) | 2011-02-25 | 2023-06-30 | Regeneron Pharma | Adam6 miševi |
MY172718A (en) | 2011-08-05 | 2019-12-11 | Regeneron Pharma | Humanized universal light chain mice |
AU2012311288B2 (en) | 2011-09-19 | 2017-08-17 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
WO2013041845A2 (en) | 2011-09-19 | 2013-03-28 | Kymab Limited | Animals, repertoires & methods |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
HUE057680T2 (hu) | 2011-10-17 | 2022-06-28 | Regeneron Pharma | Korlátozott immunglobulin-nehézlánccal rendelkezõ egerek |
GB2496375A (en) | 2011-10-28 | 2013-05-15 | Kymab Ltd | A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
CA2859408C (en) * | 2011-12-20 | 2020-06-16 | Regeneron Pharmaceuticals, Inc. | Humanized light chain mice |
MY172730A (en) | 2012-03-16 | 2019-12-11 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
WO2013144567A1 (en) | 2012-03-28 | 2013-10-03 | Kymab Limited | Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PL3597037T3 (pl) | 2012-06-12 | 2021-10-25 | Regeneron Pharmaceuticals, Inc. | Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny |
MY178882A (en) | 2013-02-20 | 2020-10-21 | Regeneron Pharma | Non-human animals with modified immunoglobulin heavy chain sequences |
PL2967013T3 (pl) | 2013-03-13 | 2019-07-31 | Regeneron Pharmaceuticals, Inc. | Mysz, w której zachodzi ekspresja ograniczonego repertuaru lekkiego łańcucha immunoglobuliny |
-
2012
- 2012-10-17 HU HUE17163115A patent/HUE057680T2/hu unknown
- 2012-10-17 PL PL17163115T patent/PL3216871T3/pl unknown
- 2012-10-17 BR BR112014008775A patent/BR112014008775A8/pt not_active Application Discontinuation
- 2012-10-17 IN IN3572CHN2014 patent/IN2014CN03572A/en unknown
- 2012-10-17 RS RS20170893A patent/RS56458B1/sr unknown
- 2012-10-17 EP EP21208060.0A patent/EP4074833A1/en active Pending
- 2012-10-17 JP JP2014535991A patent/JP6271435B2/ja active Active
- 2012-10-17 CN CN201280062449.XA patent/CN104024418B/zh active Active
- 2012-10-17 PT PT171631153T patent/PT3216871T/pt unknown
- 2012-10-17 DK DK17163115.3T patent/DK3216871T3/da active
- 2012-10-17 LT LTEP17163115.3T patent/LT3216871T/lt unknown
- 2012-10-17 RU RU2016139418A patent/RU2743589C2/ru active
- 2012-10-17 CA CA2850534A patent/CA2850534A1/en active Pending
- 2012-10-17 SG SG11201401181YA patent/SG11201401181YA/en unknown
- 2012-10-17 RS RS20220181A patent/RS62942B1/sr unknown
- 2012-10-17 SG SG10202010120XA patent/SG10202010120XA/en unknown
- 2012-10-17 EP EP17163115.3A patent/EP3216871B1/en active Active
- 2012-10-17 US US13/653,456 patent/US10246509B2/en active Active
- 2012-10-17 PL PL12783456T patent/PL2627773T3/pl unknown
- 2012-10-17 SG SG10201602904VA patent/SG10201602904VA/en unknown
- 2012-10-17 LT LTEP12783456.2T patent/LT2627773T/lt unknown
- 2012-10-17 WO PCT/US2012/060487 patent/WO2013059230A1/en active Application Filing
- 2012-10-17 CN CN201710933685.9A patent/CN108200885B/zh active Active
- 2012-10-17 EP EP12783456.2A patent/EP2627773B1/en active Active
- 2012-10-17 KR KR1020167021090A patent/KR20160098514A/ko active Search and Examination
- 2012-10-17 SI SI201231981T patent/SI3216871T1/sl unknown
- 2012-10-17 KR KR1020147013282A patent/KR20140082824A/ko active Search and Examination
- 2012-10-17 KR KR1020237045077A patent/KR20240006704A/ko not_active Application Discontinuation
- 2012-10-17 IL IL292030A patent/IL292030B2/en unknown
- 2012-10-17 KR KR1020207012383A patent/KR20200047786A/ko not_active IP Right Cessation
- 2012-10-17 ES ES12783456.2T patent/ES2640139T3/es active Active
- 2012-10-17 PT PT127834562T patent/PT2627773T/pt unknown
- 2012-10-17 KR KR1020197021940A patent/KR102148683B1/ko active IP Right Grant
- 2012-10-17 MX MX2014004354A patent/MX355062B/es active IP Right Grant
- 2012-10-17 DK DK12783456.2T patent/DK2627773T3/en active
- 2012-10-17 ES ES17163115T patent/ES2906462T3/es active Active
- 2012-10-17 KR KR1020217028212A patent/KR20210113419A/ko not_active IP Right Cessation
- 2012-10-17 SI SI201231055T patent/SI2627773T1/sl unknown
- 2012-10-17 HR HRP20220253TT patent/HRP20220253T1/hr unknown
- 2012-10-17 MY MYPI2014000810A patent/MY172946A/en unknown
- 2012-10-17 AU AU2012326283A patent/AU2012326283C1/en active Active
- 2012-10-17 RU RU2014118869/10A patent/RU2603090C2/ru active
- 2012-10-17 CN CN201710933842.6A patent/CN108207807B/zh active Active
- 2012-10-17 HU HUE12783456A patent/HUE034321T2/en unknown
-
2013
- 2013-07-17 US US13/944,286 patent/US9932398B2/en active Active
-
2014
- 2014-03-31 IL IL231819A patent/IL231819A0/en active IP Right Grant
- 2014-04-01 ZA ZA2014/02455A patent/ZA201402455B/en unknown
-
2015
- 2015-11-12 JP JP2015222017A patent/JP2016039820A/ja active Pending
-
2016
- 2016-06-17 AU AU2016204127A patent/AU2016204127C1/en active Active
-
2017
- 2017-09-11 HR HRP20171357TT patent/HRP20171357T1/hr unknown
- 2017-09-12 CY CY20171100960T patent/CY1119335T1/el unknown
- 2017-09-27 JP JP2017186356A patent/JP2017221223A/ja active Pending
-
2018
- 2018-05-30 AU AU2018203811A patent/AU2018203811B2/en active Active
- 2018-08-20 IL IL261242A patent/IL261242A/en active IP Right Grant
- 2018-12-27 JP JP2018244321A patent/JP6770568B2/ja active Active
-
2019
- 2019-02-01 US US16/265,825 patent/US11261248B2/en active Active
- 2019-04-11 IL IL265967A patent/IL265967B/en active IP Right Grant
-
2020
- 2020-04-17 US US16/851,902 patent/US20200277371A1/en not_active Abandoned
- 2020-09-25 JP JP2020161346A patent/JP7022803B2/ja active Active
- 2020-12-18 AU AU2020289846A patent/AU2020289846A1/en not_active Abandoned
-
2021
- 2021-04-08 IL IL282200A patent/IL282200B/en unknown
- 2021-12-29 JP JP2021215393A patent/JP2022048158A/ja not_active Withdrawn
-
2022
- 2022-01-19 US US17/579,185 patent/US20220177572A1/en active Pending
- 2022-02-07 CY CY20221100102T patent/CY1124972T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1124972T1 (el) | Ποντικοι με περιορισμενη βαρια αλυσιδα ανοσοσφαιρινης | |
CY1122036T1 (el) | Μη ανθρωπινα ζωα που εκφραζουν αντισωματα τα οποια εχουν μια κοινη ελαφρια αλυσιδα | |
CY1121545T1 (el) | Ποντικοι που εκφραζουν περιορισμενο ρεπερτοριο ελαφριων αλυσιδων ανοσοσφαιρινης | |
CY1124691T1 (el) | Διειδικα αντισωματα ειδικα για pd1 και τιμ3 | |
CY1126115T1 (el) | Συνδυασμος anti-lag-3 αντισωματων και anti-pd-1 αντισωματων για θεραπεια ογκων | |
CY1125029T1 (el) | Τροποποιημενοι νουκλεοζιτες, νουκλεοτιδια, και νουκλεϊκα οξεα και χρησεις αυτων | |
CY1123236T1 (el) | Αντισωματα διπλης εξειδικευσης που δεσμευονται με cd38 και cd3 | |
CY1120770T1 (el) | Ζωα πλην του ανθρωπου με τροποποιημενες αλληλουχιες βαριας αλυσιδας της ανοσοσφαιρινης | |
CY1124408T1 (el) | ΣΤΟΧΕΥΜΕΝΗ ΑΝΑΣΤΟΛΗ TGFβ | |
CY1121862T1 (el) | Αντισωματα anti-phf-tau και χρησεις αυτων | |
CY1122091T1 (el) | Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων | |
CY1118241T1 (el) | Ποντικος κοινης ελαφριας αλυσου | |
CY1122528T1 (el) | Χιμαιρικοι υποδοχεις αντιγονου bcma | |
CY1124384T1 (el) | Κατασκευες διπλοειδικων αντισωματων που δεσμευονται σε egfrviii και cd3 | |
MX353278B (es) | Raton con cadena ligera comun. | |
ECSP17040521A (es) | Anticuerpos heterodiméricos que se unen a CD3 y a antígenos tumorales | |
CY1121798T1 (el) | Αντισωματα ελαφριων αλυσιδων τροποποιημενων με ιστιδινη και γενετικα τροποποιημενα ζωα πλην του ανθρωπου για τη δημιουργια αυτων | |
CO2017006740A2 (es) | Anticuerpos anti–cd79b | |
BR112016020518A2 (pt) | receptor antigênico quimérico | |
MX2015012540A (es) | Ratón de cadena ligera común. | |
CR20170026A (es) | Anticuerpos anti-tau humanizados | |
EA201792589A1 (ru) | Антитела против cd123 и конъюгаты указанных антител | |
MX2016006529A (es) | Anticuerpos dobles especificos. | |
DK2681244T3 (da) | Cea-antistoffer | |
NZ776770A (en) | Adam6 mice |